|
Real-time Estimate
Cboe BZX
14:48:40 2026-09-14 EDT
|
5-day change | 1st Jan Change | ||
| 24.64 USD | +0.92% |
|
-2.55% | +61.23% |
| 09-01 | Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating | MT |
| 08-06 | Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| XENCOR, INC. | Bio Therapeutic Drugs | +1.11% | -2.55% | +61.23% | +190.75% | -24.58% | 1.81B |  | | |
- Stock Market
- Stocks
- XNCR Stock
- Charts Xencor, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
